Shintaro Kamo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shintaro Kamo has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Ayano Kudo
Laboratory of Small Animal Surgery, School of Veterinary Medicine Azabu University Sagamihara Kanagawa Japan
3 shared publications - Satoshi Takagi
Laboratory of Small Animal Surgery, School of Veterinary Medicine, Azabu University, Kanagawa, Japan; Azabu University Veterinary Teaching Hospital, School of Veterinary Medicine, Azabu University, Kanagawa, Japan
3 shared publications Akinori Yamauchi
2 shared publications- Satoru Konnai
Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Japan
2 shared publications - Tomohiro Okagawa
Department of Disease Control, Faculty of Veterinary Medicine, Hokkaido University, Sapporo, Japan
2 shared publications Yuma Harada
2 shared publications
Latest Publications
- Open Access
- 22 August 2026
- Published by Elsevier in SSRN Electronic Journal
Educational impact of a self-study online anesthesia monitoring simulator among veterinary students: a randomized trial and a before-and-after study
Simulation-based training in veterinary anesthesiology education is increasingly used; however, most simulators are instructor-led and require on-site participation. This randomized trial aimed to evaluate the educational impact of an online veterinary anesthesia simulator for self-directed learning by visualizing dynamic anesthetic changes and monitoring data. A total of 126 fourth-year veterinary students assigned to either a text-based learning (TL) group or a text-plus-simulator learning (TSL) group (63 per group) were included in the analysis. After a 2-week learning period, the students completed a knowledge examination and structured questionnaire. The overall examination scores did not differ between groups; however, the TSL group had a significantly lower proportion of low scores and performed better on questions requiring interpretation of anesthesia monitoring data. The TSL group reported more positive learning experiences, greater motivation, ease of understanding, and self-confidence. A non-randomized before-and-after study compared two academic-year cohorts of fifth-year veterinary students before (2024; n = 154) and after (2025; n = 129) introduction of the simulator. The post-implementation cohort reported significantly less anxiety about anesthesia procedures before feline neutering surgery training. The online anesthesia simulator promoted active learning and improved interpretation of anesthesia monitoring, while its curricular introduction was associated with reduced anxiety before clinical training with live animals. Integrating online simulation with conventional instruction may help bridge theoretical knowledge and practical anesthesia management in veterinary education.
- 22 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEducational impact of a self-study online anesthesia monitoring simulator among veterinary students: a randomized trial and a before-and-after study
Simulation-based training in veterinary anesthesiology education is increasingly used; however, most simulators are instructor-led and require on-site participation. This randomized trial aimed to evaluate the educational impact of an online veterinary anesthesia simulator for self-directed learning by visualizing dynamic anesthetic changes and monitoring data. A total of 126 fourth-year veterinary students assigned to either a text-based learning (TL) group or a text-plus-simulator learning (TSL) group (63 per group) were included in the analysis. After a 2-week learning period, the students completed a knowledge examination and structured questionnaire. The overall examination scores did not differ between groups; however, the TSL group had a significantly lower proportion of low scores and performed better on questions requiring interpretation of anesthesia monitoring data. The TSL group reported more positive learning experiences, greater motivation, ease of understanding, and self-confidence. A non-randomized before-and-after study compared two academic-year cohorts of fifth-year veterinary students before (2024; n = 154) and after (2025; n = 129) introduction of the simulator. The post-implementation cohort reported significantly less anxiety about anesthesia procedures before feline neutering surgery training. The online anesthesia simulator promoted active learning and improved interpretation of anesthesia monitoring, while its curricular introduction was associated with reduced anxiety before clinical training with live animals. Integrating online simulation with conventional instruction may help bridge theoretical knowledge and practical anesthesia management in veterinary education.
- 12 February 2026
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 24 (2) , 284-292
Prognostic Significance of Tumour Infiltrating Lymphocytes in Canine Oral Malignant Melanoma Treated With Anti‐Programmed Cell Death Ligand 1 ( PD ‐ L1 ) Antibody Therapy
Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic strategy for canine oral malignant melanoma (OMM). However, only a subset of cases have shown clinical responses. Additionally, predictive biomarkers for the efficacy of ICIs in veterinary medicine are yet to be established. Tumour‐infiltrating lymphocytes (TILs) are predictive biomarkers for ICI therapy in humans. In this study, we aimed to investigate the predictive utility of TILs for canine OMM treated with ICI therapy. Immunohistochemistry was performed on pre‐treatment pathological tissues to detect cells positive for CD3 (pan‐T cell marker), Granzyme B (cytotoxic T lymphocyte or natural killer cell marker) and Foxp3 (regulatory T cell marker). Further, we analysed the infiltration patterns of these cells and their prognostic utility for anti‐programmed cell death ligand 1 (PD‐L1) antibody therapy. There were variances in the infiltration levels of each TIL subset; further, we observed several TIL infiltration patterns in canine OMM. Survival analysis revealed that high infiltration of CD3 + and Granzyme B + cells was significantly associated with prolonged progression‐free survival and overall survival. Furthermore, the immune cell composition ratio, which reflected the balance between cytotoxic and regulatory cells, was significantly associated with survival time. These findings suggest that canine OMM exhibits immunological phenotypes analogous to those observed in human cancers. Taken together, the TIL profile holds significant potential as a prognostic biomarker for canine OMM treated with anti‐PD‐L1 antibody therapy.
- 12 February 2026
- Published by Wiley in Veterinary and Comparative Oncology
- Vol. 24 (2) , 284-292
Prognostic Significance of Tumour Infiltrating Lymphocytes in Canine Oral Malignant Melanoma Treated With Anti‐Programmed Cell Death Ligand 1 ( PD ‐ L1 ) Antibody Therapy
Immune checkpoint inhibitors (ICIs) have emerged as a promising therapeutic strategy for canine oral malignant melanoma (OMM). However, only a subset of cases have shown clinical responses. Additionally, predictive biomarkers for the efficacy of ICIs in veterinary medicine are yet to be established. Tumour‐infiltrating lymphocytes (TILs) are predictive biomarkers for ICI therapy in humans. In this study, we aimed to investigate the predictive utility of TILs for canine OMM treated with ICI therapy. Immunohistochemistry was performed on pre‐treatment pathological tissues to detect cells positive for CD3 (pan‐T cell marker), Granzyme B (cytotoxic T lymphocyte or natural killer cell marker) and Foxp3 (regulatory T cell marker). Further, we analysed the infiltration patterns of these cells and their prognostic utility for anti‐programmed cell death ligand 1 (PD‐L1) antibody therapy. There were variances in the infiltration levels of each TIL subset; further, we observed several TIL infiltration patterns in canine OMM. Survival analysis revealed that high infiltration of CD3 + and Granzyme B + cells was significantly associated with prolonged progression‐free survival and overall survival. Furthermore, the immune cell composition ratio, which reflected the balance between cytotoxic and regulatory cells, was significantly associated with survival time. These findings suggest that canine OMM exhibits immunological phenotypes analogous to those observed in human cancers. Taken together, the TIL profile holds significant potential as a prognostic biomarker for canine OMM treated with anti‐PD‐L1 antibody therapy.
- Open Access
- 2 September 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (9) , 850
Exploratory, Randomized, Dose-Response Study of the Anti-PD-L1 Antibody HFC-L1/c4G12 in Dogs with Pulmonary Metastatic Oral Malignant Melanoma
Oral malignant melanoma (OMM) is a highly aggressive malignancy in dogs. The development of effective systemic therapies is urgently required to improve the treatment of canine OMM. Immunotherapy using immune checkpoint inhibitors (ICIs) has been investigated in canines following their dramatic success in human cancer treatment; however, there is still a need for extensive veterinary clinical studies to clarify and optimize their clinical benefits. Among the ICIs under development for canine cancer immunotherapy, c4G12 (HFC-L1), a canine chimeric anti-PD-L1 antibody, has shown promising efficacy in dogs with pulmonary metastatic OMM in previous clinical studies. However, the optimal dose of HFC-L1/c4G12 has not yet been determined. To explore the dose–response relationship of HFC-L1, a multicenter, randomized clinical study was conducted using three different doses (2, 5, or 10 mg/kg via intravenous infusion every 2 weeks) to treat dogs with pulmonary metastatic OMM (n = 8–9 per group). The safety profiles were similar among the dose groups, and numerically longer median overall survival was achieved in the higher dose groups (5 and 10 mg/kg) than in the 2 mg/kg group. Although the study was exploratory in nature with a small sample size, 5–10 mg/kg should be considered the preferred dose in future clinical studies using HFC-L1.
- 2 September 2025
- Published by MDPI AG in Veterinary Sciences
- Vol. 12 (9) , 850
Open AccessExploratory, Randomized, Dose-Response Study of the Anti-PD-L1 Antibody HFC-L1/c4G12 in Dogs with Pulmonary Metastatic Oral Malignant Melanoma
Oral malignant melanoma (OMM) is a highly aggressive malignancy in dogs. The development of effective systemic therapies is urgently required to improve the treatment of canine OMM. Immunotherapy using immune checkpoint inhibitors (ICIs) has been investigated in canines following their dramatic success in human cancer treatment; however, there is still a need for extensive veterinary clinical studies to clarify and optimize their clinical benefits. Among the ICIs under development for canine cancer immunotherapy, c4G12 (HFC-L1), a canine chimeric anti-PD-L1 antibody, has shown promising efficacy in dogs with pulmonary metastatic OMM in previous clinical studies. However, the optimal dose of HFC-L1/c4G12 has not yet been determined. To explore the dose–response relationship of HFC-L1, a multicenter, randomized clinical study was conducted using three different doses (2, 5, or 10 mg/kg via intravenous infusion every 2 weeks) to treat dogs with pulmonary metastatic OMM (n = 8–9 per group). The safety profiles were similar among the dose groups, and numerically longer median overall survival was achieved in the higher dose groups (5 and 10 mg/kg) than in the 2 mg/kg group. Although the study was exploratory in nature with a small sample size, 5–10 mg/kg should be considered the preferred dose in future clinical studies using HFC-L1.